Navigation Links
SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor
Date:11/20/2008

DUBLIN, Calif., Nov. 20 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that it has received clearance to initiate clinical trials with SGI-1776, an inhibitor of Pim kinases. The clearance of its Original Investigational New Drug Application ("IND") triggers a $5.2 million milestone payment to the former stockholders of Montigen Pharmaceuticals, Inc. The milestone payment will consist of $2.8 million in cash payments and the issuance of approximately $2.4 million in equity, representing approximately 1.5 million shares of SuperGen common stock.

SuperGen will initiate a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic profile of SGI-1776, a novel, orally administered, small molecule anticancer compound. The first in human clinical trial program will enroll patients with solid tumors with specific emphasis on hormone refractory prostate cancer and refractory non-Hodgkin's lymphomas. These solid tumor types have been reported to overexpress the Pim kinase family of proteins at a high frequency. Overexpression of Pim-1 kinase has been shown to be a marker of poor prognosis in these tumors. A second Phase I/II study is being planned in patients with refractory leukemias in which Pim kinases are also overexpressed, and correlated with poor prognosis and drug resistance.

"We are pleased to acknowledge FDA's clearance of our IND application to enter what we believe is the world's first investigational product targeted to inhibit PIM kinases into Phase I clinical trials," said Dr. James Manuso, SuperGen's President and Chief Executive Officer. "The clearance of the SGI-1776 IND application represents a validation of our Company's CLIMB(TM) technology platform and its ability to
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SuperGen Reports 2008 Third Quarter Financial Results
2. SuperGen to Announce 2008 Third Quarter Financial Results November 4, 2008
3. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
4. SuperGen to Present Data at EORTC-NCI-AACR
5. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
6. SuperGen Reports 2008 Second Quarter Financial Results
7. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
8. SuperGen Reports 2008 First Quarter Financial Results
9. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
10. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
11. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 In November 2012, the European ... Evaluation Report (PBRER) in a new PSUR – responding to ... benefit-risk profile of a drug. Adopted in many regions, the ... Present a comprehensive and critical analysis of new or ... Highlight any new evidence of the potential benefits of ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics ... ICOTF), today reported results of its Oral Amphotericin ... HIV reservoirs.  The study, conducted by ImmuneCarta®, the ... in vitro effectiveness of Oral Amp B ... present in individuals despite intensive treatment with antiretroviral ...
(Date:8/18/2014)... August 19, 2014 2014 Deep ... is a professional and in-depth research report on ... Linalool information, including its definition, classification, application, ... overview. This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic situation ...
(Date:8/18/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a life ... products for advanced microarray diagnostics, today announced it will ... at 2:00 pm ET.  During the ... brief review of SQI,s recent commercialization progress and then ... veteran recently appointed to the Board of Directors of ...
Breaking Biology Technology:Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3
... Quarterly presents a 360-degree look at the "state of ... drugs. This CQ Forum will include a panel discussion ... regarding the complex structures of biologics products vs. traditional ... these products save money for consumers? What is the ...
... June 15 Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: ... new class of small molecule compounds based on endogenous adrenal ... James M. Frincke Ph.D. as President and CEO of Hollis-Eden ... company,s board of directors. , , Dr. Frincke joined ...
... June 15 Nanopoint Inc., an award-winning developer ... announced that effective immediately its cellTRAY Imaging System ... European marketplace. Nanopoint,s cellTRAY Imaging and Fluidics Systems ... including drug discovery, assisted reproductive technology (ART), stem ...
Cached Biology Technology:Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO 2Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO 3Nanopoint Applies CE Mark to Its cellTRAY(R) Imaging and Microfluidics Systems 2
(Date:8/19/2014)... lemur. It,s not an African Bush Baby or even a ... downright "cool" primate from Southeast Asia. , "It,s really not ... Brown, curator-in-charge at the University of Kansas, Biodiversity Institute. "A ... body; a long tail with a furry tuft at the ... a bit like the disks on the digits of tree ...
(Date:8/19/2014)... retail seafood counters in 10 different states show ... to unexpectedly high levels of mercury, a harmful ... fish of the same species, but from a ... according to new research by University of Hawai,i ... is essential to allow consumers to choose sustainable ...
(Date:8/19/2014)... identified a biomarker strongly associated with basal-like breast ... to many types of chemotherapy. The biomarker, a ... new therapeutics designed to treat this often deadly ... from The Cancer Genome Atlas, molecular biologists Curt ... computational and bioinformatics techniques to detect patterns of ...
Breaking Biology News(10 mins):Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3
... and vegetables instead of cookies and soda pop. Consider ... applaud a lunchtime workout rather than criticizing the cut ... encourages walking the stairs instead of riding the elevator. ... by Community Health Councils, Inc. (CHC) in Los Angeles ...
... Cold Spring Harbor Laboratory on Long Island have identified which ... the chief target of the widely prescribed antidepressant Prozac. This ... for depression, with fewer side effects, to be developed. , ... the factors that control how, when, and where new neurons ...
... tumor and settles in a new location, where it ... assays for this process, which is known as metastasis, ... across the surface of a matrix, traveling in a ... approach misses some crucial phenomena. , Working in the ...
Cached Biology News:UCLA study of community health project shows how group dynamics affect fitness, eating habits 2UCLA study of community health project shows how group dynamics affect fitness, eating habits 3Prozac's target revealed 23-D model reveals secrets of metastasis 2
... The Varian 500-MS LC Ion Trap ... high-throughput LC/MS analysis where sensitivity, reliability ... 500-MS provides a robust platform for ... mass resolution, and mass stability reflect ...
... This modular benchtop fume ... fumes, allowing safe indoor release ... remove most organic contaminants. Configurations ... horizontal flow; options include final ...
... for biological safety labs (BSL) and ... Class 10/ISO 3) and easy sterilization. ... surfaces that are easy to wipe ... simplify cleaning. Unique double-wall panel design ...
... The new Hummingbird has the ability to quickly ... plate makes it a perfect candidate for inclusion ... simple OCX interface supplied with all the Cartesian ... store. Hummingbirds ability to copy plates in ...
Biology Products: